Treatment Options in Patients Suffering from Hemolytic-Uremic Syndrome: The Serbian Military Medical Academy Experience

Online veröffentlicht: 20. Sept. 2022

Seitenbereich: 237 - 242

Eingereicht: 27. Juni 2019

Akzeptiert: 16. Sept. 2019

DOI: https://doi.org/10.2478/sjecr-2019-0060

Schlüsselwörter

Hemolytic-uremic syndrome, atypical hemolytic-uremic syndrome, C3, corticosteroids, plasmapheresi

© 2022 Jelena Tadic et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.